August 10, 2022

Numinus files an international patent application on the production process of psychedelics

The filing would provide additional protection to intellectual property already submitted to the USPTO

VANCOUVER, BC, June 22, 2022 /PRNewswire/ – Numinus Wellness Inc. (“Numinus” or the “Company”) (TSX: NUMI) (OTCQX: NUMIF), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic therapies, today announced that its subsidiary Numinus Bioscience Inc. (“Numinus Bioscience “) filed a patent application with the World Intellectual Property Organization (WIPO), an agency of the United Nations, for a rapid production process of Psilocybe and other species of mushrooms containing psilocybin and other compounds.

A provisional patent application for the process was filed with the United States Patent and Trademark Office (USPTO) on June 24, 2021. With this additional filing, international patent protection would extend to all WIPO Member States that have signed the Patent Cooperation Treaty (PCT), including Australia, Germany, Netherlands and the UKwhere psychedelic research is currently active.

“WIPO is an important global forum that reassures member state patent offices. Numinus is confident that strong evidence supporting the production process will further inform regulators when considering policy changes to make therapies and more accessible psychedelic-assisted products,” said Sharan Sidhu, vice president, scientific research, innovation and laboratory operations, Numinus. “We look forward to advancing current research and paving the way for eventual commercialization and mainstream access.”

The goal of the process is to significantly increase the production of therapeutic products for use in psychedelic-assisted therapy, while reducing product variability, increasing production efficiency, and ultimately reducing marketing costs. . Since the initial filing, datasets validating the process for additional fungi have been completed, expanding its potential application and scope from psilocybin to other active compounds.

“This application is part of Numinus’ long-term intellectual property strategic focus on scalable and sustainable production that advances the research, development and delivery of innovative psychedelic-derived formulations in North America and beyond,” said Payton NyquvestFounder and CEO, Numinus.

About Numinus

Numinus Wellness helps people heal and feel great through the development and delivery of innovative mental health care and access to safe, evidence-based psychedelic therapies. The Numinus model – comprising psychedelic production, research and clinical care – is at the forefront of a transformation aimed at healing rather than managing the symptoms of depression, anxiety, trauma, pain and addiction. At Numinus, we lead the integration of psychedelic-assisted therapies into mainstream clinical practice and lay the foundation for a healthier society.

Learn more about numinus.com and follow us on LinkedIn, Facebook, Twitterand instagram.

Disclaimer

Neither Numinus Wellness Inc. nor any of its subsidiaries is a professional corporation licensed to practice health services. In jurisdictions where health services may only be provided by a company if that company holds a valid license to do so, Numinus and its subsidiaries operate in a management services function to affiliated professional companies, which provide health services to patients. Numinus and its subsidiaries provide healthcare services directly to patients in jurisdictions authorized to do so.

Forward-looking statements

Statements and other information in this press release regarding anticipated future events are forward-looking statements. Forward-looking statements are often, but not always, identified by the use of words such as “seek”, “anticipate”, “believe”, “plan”, “estimate”, “expect” and “have the intention” and statements that an event “may”, “shall”, “should”, “might” or “could” occur or other similar expressions. Forward-looking statements are subject to risks and uncertainties and other factors that could cause actual results to differ materially from those contained in the forward-looking statements. Forward-looking statements are based on management’s estimates and opinions as of the date the statements are made. The Company undertakes no obligation to update forward-looking statements even if circumstances or management’s estimates or opinions should change, except as required by applicable law. Investors should not place undue reliance on forward-looking statements.

Quote

Show original content:https://www.prnewswire.com/news-releases/numinus-applies-for-international-patent-filing-of-psychedelics-production-process-301572540.html

SOURCE Numinus Wellness Inc.